These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 16527838

  • 1. Activin-A binds follistatin and type II receptors through overlapping binding sites: generation of mutants with isolated binding activities.
    Harrison CA, Chan KL, Robertson DM.
    Endocrinology; 2006 Jun; 147(6):2744-53. PubMed ID: 16527838
    [Abstract] [Full Text] [Related]

  • 2. An activin mutant with disrupted ALK4 binding blocks signaling via type II receptors.
    Harrison CA, Gray PC, Fischer WH, Donaldson C, Choe S, Vale W.
    J Biol Chem; 2004 Jul 02; 279(27):28036-44. PubMed ID: 15123686
    [Abstract] [Full Text] [Related]

  • 3. Residues in the C-terminal region of activin A determine specificity for follistatin and type II receptor binding.
    Fischer WH, Park M, Donaldson C, Wiater E, Vaughan J, Bilezikjian LM, Vale W.
    J Endocrinol; 2003 Jan 02; 176(1):61-8. PubMed ID: 12525250
    [Abstract] [Full Text] [Related]

  • 4. An activin-A/C chimera exhibits activin and myostatin antagonistic properties.
    Muenster U, Harrison CA, Donaldson C, Vale W, Fischer WH.
    J Biol Chem; 2005 Nov 04; 280(44):36626-32. PubMed ID: 16129674
    [Abstract] [Full Text] [Related]

  • 5. Structural basis for the inhibition of activin signalling by follistatin.
    Harrington AE, Morris-Triggs SA, Ruotolo BT, Robinson CV, Ohnuma S, Hyvönen M.
    EMBO J; 2006 Mar 08; 25(5):1035-45. PubMed ID: 16482217
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Cripto forms a complex with activin and type II activin receptors and can block activin signaling.
    Gray PC, Harrison CA, Vale W.
    Proc Natl Acad Sci U S A; 2003 Apr 29; 100(9):5193-8. PubMed ID: 12682303
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Differential binding and neutralization of activins A and B by follistatin and follistatin like-3 (FSTL-3/FSRP/FLRG).
    Schneyer A, Schoen A, Quigg A, Sidis Y.
    Endocrinology; 2003 May 29; 144(5):1671-4. PubMed ID: 12697670
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Expression of activin and inhibin subunits, receptors and binding proteins in human adrenocortical neoplasms.
    Hofland J, Timmerman MA, de Herder WW, van Schaik RH, de Krijger RR, de Jong FH.
    Clin Endocrinol (Oxf); 2006 Dec 29; 65(6):792-9. PubMed ID: 17121532
    [Abstract] [Full Text] [Related]

  • 15. Identification of a binding site on the type II activin receptor for activin and inhibin.
    Gray PC, Greenwald J, Blount AL, Kunitake KS, Donaldson CJ, Choe S, Vale W.
    J Biol Chem; 2000 Feb 04; 275(5):3206-12. PubMed ID: 10652306
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Tissue-specific binding of radiolabeled activin A by activin receptors and follistatin in postimplantation rat and mouse embryos.
    Roberts VJ, Bentley CA, Guo Q, Matzuk MM, Woodruff TK.
    Endocrinology; 1996 Oct 04; 137(10):4201-9. PubMed ID: 8828478
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Activins bind and signal via bone morphogenetic protein receptor type II (BMPR2) in immortalized gonadotrope-like cells.
    Rejon CA, Hancock MA, Li YN, Thompson TB, Hébert TE, Bernard DJ.
    Cell Signal; 2013 Dec 04; 25(12):2717-26. PubMed ID: 24018044
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.